Bridgewater, NJ, United States of America

Jean McLarty

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Genzyme Corporation. Active years: 2022.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Jean McLarty

Introduction

Jean McLarty is an accomplished inventor based in Bridgewater, NJ (US). He has made significant contributions to the field of biotechnology, particularly in methods that enhance cell viability in production bioreactors. His innovative work has the potential to impact various applications in the life sciences industry.

Latest Patents

Jean McLarty holds 1 patent for his invention titled "Methods for improving cell viability in a production bioreactor." This patent provides methods for predicting the effect of a concentration of a sensitizer on cell viability, improving cell viability in production bioreactors, predicting cell viability, and culturing cells in these bioreactors. His work addresses critical challenges in bioprocessing and cell culture.

Career Highlights

Jean is currently employed at Genzyme Corporation, a leading biotechnology company known for its innovative therapies. His role at Genzyme allows him to apply his expertise in bioprocessing and contribute to the development of advanced biotechnological solutions.

Collaborations

Jean collaborates with talented professionals in his field, including Jonathan Wang and Neha Shah. Their combined expertise fosters a productive environment for innovation and research.

Conclusion

Jean McLarty's contributions to biotechnology through his patent and work at Genzyme Corporation highlight his role as a key innovator in the industry. His efforts in improving cell viability in production bioreactors are paving the way for advancements in biotechnological applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…